NLRX1 (Total Importance: 8.01 in ALS, 5.89 in MS) showed opposing effects, increasing risk in MS (OR: 1.001; 95% CI: 1.000–1.002; p = 0.014) but reducing it in ALS (OR: 0.929; 95% CI: 0.879–0.982; p = 0.009). Here, NLRX1 is linked to myeloid sarcoma.